Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis – A phase II study
ID Number 12-1809Principal Investigator(s)
John O. Mascarenhas
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to find out if adding the study drug Ruxolitinib (INC424) to a combination of other chemotherapeutic drugs (Fludarabine and Busulfan) before removing your bone marrow, treating it for your disease, and then returning it to your body from a donor (bone marrow transplantation) will be successful in people who have advanced primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF), collectively known as myelofibrosis (MF). MF is a disorder in which bone marrow tissue develops in abnormal sites because the bone marrow itself undergoes fibrosis or scarring. This study plans to add the drug Ruxolitinib to further aid in reducing pre-transplant spleen size, improve physical performance levels and reduce adverse events (side effects) related to the transplant. Ruxolitinib is a drug that is approved by the Federal Drug Administration (FDA) for the treatment of patients with advanced forms of myelofibrosis. Using Ruxolitinib prior to stem cell transplantation is experimental.
You qualify to take part in this research because you have a blood disorder called myelofibrosis (MF), or myelofibrosis following polycythemia vera (PV), or following essential thrombocythemia (ET), and need a stem cell transplant.
Recruiting Patients: Yes